1. Home
  2. Products
  3. Customized ADCs
  4. SLITRK6
  5. Anti-SLITRK6 (clone AGS15)-Mc-VC-MMAE ADC

Anti-SLITRK6 (clone AGS15)-Mc-VC-MMAE ADC (CAT#: ADC-W-435)

This ADC product is comprised of an anti-SLITRK6 monoclonal antibody (clone AGS15) conjugated via a Mc-VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • AGS15
  • Name
  • SLITRK6
  • Alternative Names
  • SLITRK6; SLIT and NTRK-like family, member 6; DFNMYP; SLIT and NTRK-like protein 6; 4832410J21Rik; slit and trk like gene 6;
  • Target Entrez Gene ID
  • 84189
  • Overview
  • This gene encodes a member of the SLITRK protein family. Members of this family are integral membrane proteins that are characterized by two N-terminal leucine-rich repeat (LRR) domains and a C-terminal region that shares homology with trk neurotrophin receptors. This protein functions as a regulator of neurite outgrowth required for normal hearing and vision. Mutations in this gene are a cause of myopia and deafness.
  • Overview
  • Human Anti-SLITRK6 lgG2 Antibody, clone # AGS15
  • Clone #
  • AGS15
  • Species Reactivity
  • Human
  • Name
  • mc-VC (maleimidocaproyl-valine-citrulline)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • MMAE (Monomethyl auristatin E)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-435. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-489 Anti-SLITRK6-MMAE ADC protease-cleavable linker MMAE (Monomethyl auristatin E)
CAT# Product Name Linker Payload
ADC-W-446 Anti-CD70 (clone h1F6)-Mc-VC-PBD ADC mc-VC (maleimidocaproyl-valine-citrulline) pyrrolobenzodiazepine (PBD) dimers
ADC-W-430 Anti-PMEL (clone 31D1.6.7)-Mc-VC-MMAE ADC mc-VC (maleimidocaproyl-valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-W-432 Anti-FOLH1 (MLN591)-Mc-VC-MMAE ADC mc-VC (maleimidocaproyl-valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-W-343 Anti-TNFRSF8 (cAC10)-Mc-VC-MMAE ADC mc-VC (maleimidocaproyl-valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-W-364 Anti-CD70 (clone 1F6-C4v2)-Mc-VC-MMAF ADC mc-VC (maleimidocaproyl-valine-citrulline) MMAF (Monomethyl auristatin F)
CAT# Product Name Linker Payload
ADC-W-536 Anti-EDNRB (endothelin B)-VC-MMAE ADC VC (valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-AA-003 anti-HIgG(Fc)-C-MMAE ADC Cleavable linkers MMAE (Monomethyl auristatin E)
ADC-AA-017 anti-HIgG(Fab)-C-MMAE ADC Cleavable linkers MMAE (Monomethyl auristatin E)
ADC-W-499 Anti-SLC34A2 (Lifastuzumab)-VC-MMAE ADC mc-VC-PABC MMAE (Monomethyl auristatin E)
ADC-W-565 Anti-EDNRB-VC-MMAE ADC VC (valine-citrulline) MMAE (Monomethyl auristatin E)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.